OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
BUENA, N.J., May 01, 2018 -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at Deutsche Bank’s 43rd Annual Health Care Conference. The Conference is taking place May 8-9, 2018 at the Intercontinental Hotel, Boston.
Damian Finio, Chief Financial Officer of Teligent, Inc., will present on Tuesday, May 8th at 12:50 p.m. ET.
The presentation will be webcast and accessible online via the investors section of the Company's website at www.teligent.com. A replay will be available for 30 days.
About Teligent, Inc.
Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Learn more on our website www.teligent.com.
Contact:
Damian Finio
Teligent, Inc.
(856) 336-9117
www.teligent.com
